(Q35797107)

10 August 2017

title

The incidence and outcome of photodynamic therapy for macular degeneration in the Northern region of the UK. (English)

1 reference

10 August 2017

1 reference

Talks SJ

1

1 reference

10 August 2017

Setty R

series ordinal

2

1 reference

10 August 2017

Clarke L

series ordinal

3

1 reference

10 August 2017

publication date

1 June 2004

1 reference

10 August 2017

1 reference

10 August 2017

volume

18

1 reference

10 August 2017

issue

6

1 reference

10 August 2017

page(s)

588-594

1 reference

World blindness: a 21st century perspective.

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6700709

Reviewers, authors, and editors: balance of power

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6700709

Treatment of subfoveal choroidal neovascularisation in age related macular degeneration: focus on clinical application of verteporfin photodynamic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6700709

Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynami

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6700709

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6700709

Identifying the proportion of age related macular degeneration patients who would benefit from photodynamic therapy with verteporfin (Visudyne).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6700709

The Framingham Eye Study. I. Outline and major prevalence findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6700709

Prevalence of age-related maculopathy in Australia. The Blue Mountains Eye Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6700709

The prevalence of age-related maculopathy by geographic region and ethnicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6700709

Laser treatments with verteporfin therapy and its potential impact on retinal practices

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6700709

Eligibility for treatment and angiographic features at the early stage of exudative age related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6700709

Senile disciform macular degeneration: features indicating suitability for photocoagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6700709

Variability in fluorescein angiography interpretation for photodynamic therapy in age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6700709

Verteporfin photodynamic therapy in the UK: implications of the NICE appraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6700709

Prevalence of ocular disease in a population study of subjects 65 years old and older.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6700709

7 January 2021

Prevalence of age-related maculopathy at two points in time in an elderly British population

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6700709

7 January 2021

Prevalence of age-related maculopathy. The Beaver Dam Eye Study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6700709

7 January 2021

The prevalence of age-related maculopathy in the Rotterdam Study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6700709

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6700709

7 January 2021

Identifiers

DOI

10.1038/SJ.EYE.6700709

1 reference

10 August 2017

1 reference